FibroBiologics FY2025 EPS Forecast Raised by HC Wainwright

FibroBiologics, Inc. (NASDAQ:FBLG) – Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of FibroBiologics in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.44) for the year, up from their previous estimate of ($0.46). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.76) EPS.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01.

FBLG has been the subject of a number of other research reports. Rodman & Renshaw started coverage on FibroBiologics in a report on Thursday, December 12th. They issued a “buy” rating and a $12.00 target price for the company. D. Boral Capital reissued a “buy” rating and set a $16.00 price objective on shares of FibroBiologics in a report on Tuesday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $13.00.

FibroBiologics Stock Performance

FibroBiologics stock opened at $0.88 on Thursday. The stock’s 50 day moving average price is $1.23 and its 200 day moving average price is $2.11. FibroBiologics has a 1-year low of $0.85 and a 1-year high of $13.59.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in FBLG. Geode Capital Management LLC boosted its position in shares of FibroBiologics by 90.0% in the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock worth $1,854,000 after buying an additional 284,047 shares in the last quarter. Barclays PLC lifted its holdings in shares of FibroBiologics by 363.2% in the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after purchasing an additional 31,331 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of FibroBiologics in the fourth quarter valued at approximately $30,000. Jane Street Group LLC purchased a new position in shares of FibroBiologics during the 3rd quarter worth approximately $37,000. Finally, State Street Corp raised its position in shares of FibroBiologics by 26.5% during the 3rd quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after purchasing an additional 99,789 shares during the last quarter.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.